文献速递急性肾损伤

临床与临床前研究中急性肾损伤判定方法的差异

Differences in acute kidney injury ascertainment for clinical and preclinical studies.
PubMed 文献 · Nephrol Dial Transplant · 2017-01-01

本系统综述纳入151项临床与临床前干预性研究(临床76项、临床前75项),比较两者在急性肾损伤生物标志物用于入选标准或结局评估方面的差异。临床研究多集中于心脏手术(38.1%)和对比剂相关急性肾损伤(17.1%),临床前研究多集中于缺血再灌注损伤或药物性急性肾损伤(各42.6%)。临床研究57.8%采用标准标准定义急性肾损伤,仅19.7%在肾损伤定义中使用生物标志物;临床前研究多数依据血肌酐和血尿素氮升高定义急性肾损伤,32%在定义中纳入生物标志物。

要点

  • 临床研究57.8%采用标准标准定义急性肾损伤,仅19.7%在定义中使用生物标志物。
  • 临床前研究多数依据血肌酐和血尿素氮升高定义急性肾损伤,32%在定义中纳入生物标志物。
  • 临床前研究较临床研究更可能将急性肾损伤生物标志物作为主要终点,比值比2.31(95%置信区间1.17-4.59),P=0.016。

核心结论

  • 临床与临床前研究在急性肾损伤生物标志物的应用上存在明显差异,可能影响临床前研究结果向临床实践的转化。

研究设计与样本

  • 系统综述,纳入151项临床与临床前干预性研究(临床76项、临床前75项),这些研究在入选标准和/或结局评估中考虑了急性肾损伤生物标志物。

主要发现

  • 临床研究中38.1%聚焦于心脏手术,17.1%聚焦于对比剂相关急性肾损伤;临床前研究中42.6%聚焦于缺血再灌注损伤,42.6%聚焦于药物性急性肾损伤。
  • 57.8%的临床研究采用标准标准定义急性肾损伤,其中仅19.7%在肾损伤定义中使用急性肾损伤生物标志物。
  • 临床前研究多数依据血肌酐和血尿素氮升高定义急性肾损伤,32%在定义中纳入生物标志物。
  • 近10年临床与临床前研究将生物标志物作为主要终点的比例均未显著增加。
  • 临床前研究较临床研究更可能将急性肾损伤生物标志物作为主要终点,比值比2.31(95%置信区间1.17-4.59),P=0.016。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute kidney injury (AKI) is a common clinical condition directly associated with adverse outcomes. Several AKI biomarkers have been discovered, but their use in clinical and preclinical studies has not been well examined. This study aims to investigate the differences between clinical and preclinical studies on AKI biomarkers. METHODS: We performed a systematic review of clinical and preclinical interventional studies that considered AKI biomarkers in enrollment criteria and/or outcome assessment and described the main differences according to their setting, the inclusion of biomarkers in the definition of AKI and the use of biomarkers as primary or secondary end points. RESULTS: In the 151 included studies (76 clinical, 75 preclinical), clinical studies have prevalently focused on cardiac surgery (38.1%) and contrast-associated AKI (17.1%), while the majority of preclinical studies have focused on ether ischemia-reperfusion injury or drug-induced AKI (42.6% each). A total of 57.8% of clinical studies defined AKI using the standard criteria and only 19.7% of these studies used AKI biomarkers in the definition of renal injury. Conversely, the majority of preclinical studies defined AKI according to the increase in serum creatinine and blood urea nitrogen, and 32% included biomarkers in that definition. The percentage of both clinical and preclinical studies with biomarkers as a primary end point has not significantly increased in the last 10 years; however, preclinical studies are more likely to use AKI biomarkers as a primary end point compared with clinical studies [odds ratio 2.31 (95% confidence interval 1.17-4.59); P = 0.016]. CONCLUSION: Differences between clinical and preclinical studies are evident and may affect the translation of preclinical findings in the clinical setting.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Fiorentino M, Castellano G, Kellum JA, et al. Differences in acute kidney injury ascertainment for clinical and preclinical studies. Nephrol Dial Transplant. 2017. PMID: 28371878. doi:10.1093/ndt/gfx002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。